Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neovascular endothelium refers to the endothelial cells lining newly formed blood vessels. These cells exhibit distinct molecular and functional characteristics compared to mature endothelium, playing a critical role in angiogenesis, vascular permeability, and immune cell trafficking. The neovascular endothelium is a key target in diseases characterized by abnormal angiogenesis, such as cancer, ocular diseases, and chronic inflammation, where targeted therapies aim to inhibit vessel formation and disrupt disease progression.
Varies depending on the specific drug and target; examples include inhibition of VEGFR2 signaling, disruption of integrin-mediated cell adhesion, and targeted delivery of cytotoxic agents to neovascular endothelium.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neovascular Endothelium (N/A).